Status:
TERMINATED
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
Lead Sponsor:
Kadmon Corporation, LLC
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study involves treatment with KD019 or erlotinib in patients with Non-small cell lung cancer (NSCLC) who have progressed after first- or second- line chemotherapy. It is hypothesized that KD019 c...
Eligibility Criteria
Inclusion
- For Eligibility subjects must have:
- failed one or two previous courses of therapy.
- have no active brain metastasis. Treated non-active brain metastasis are acceptable.
- cannot have received an Epidermal Growth Factor Receptors inhibitor (Tarceva \[erlotinib\] or Iressa \[gefitinib\]) in the past.
- has demonstrated progressive disease.
Exclusion
Key Trial Info
Start Date :
December 14 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 25 2013
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT01487174
Start Date
December 14 2011
End Date
July 25 2013
Last Update
May 13 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale Cancer Center
New Haven, Connecticut, United States, 06519
2
San Juan Oncology Associates
Farmington, New Mexico, United States, 87401